FGL Peptide

FGL is a 15-amino acid peptide derived from the second fibronectin type III (FNIII) module of the neural cell adhesion molecule (NCAM). The sequence corresponds to a binding epitope on NCAM that mediates interactions with fibroblast growth factor receptors (FGFRs), and the synthetic FGL peptide acts as a functional mimetic of this NCAM-FGFR interaction - capable of activating FGFR1 and FGFR2 and triggering downstream signalling without the requirement for full-length NCAM protein.

The NCAM-FGFR interaction that FGL mimics is fundamentally important in neural development and adult synaptic plasticity. NCAM (CD56) is a cell adhesion molecule expressed on neurons and glia that mediates cell-cell adhesion, neurite outgrowth guidance, and synapse formation. Post-developmentally, NCAM undergoes polysialylation (attachment of long chains of sialic acid polymers, PSA-NCAM) that reduces its adhesive properties and promotes synaptic plasticity by enabling structural remodelling of synapses during learning and memory. The NCAM-FGFR interaction is one mechanism through which NCAM signals beyond simple cell adhesion to regulate intracellular pathways.

The discovery that a small peptide mimicking the NCAM-FGFR binding site could activate FGFR signalling and produce neuroplasticity effects comparable to full-length NCAM application came from research at the University of Copenhagen by Elisabeth Bock's group in the late 1990s and 2000s. The key finding was that FGL peptide, when applied to hippocampal slices, enhanced long-term potentiation (LTP) - the activity-dependent strengthening of synaptic connections that is the cellular basis of memory formation. This LTP enhancement was FGFR-dependent and accompanied by PKC and MEK/ERK activation.

The aging brain shows characteristic declines in NCAM expression and polysialylation, accompanied by deficits in LTP and spatial memory. The hypothesis that FGL peptide could compensate for this decline - providing FGFR activation that aging neurons fail to receive from their own declining NCAM expression - has been tested extensively in aged rodent models. Studies consistently show that aged animals treated with FGL peptide perform significantly better on hippocampal-dependent memory tasks (Morris Water Maze, novel object recognition) and show LTP that resembles younger animals. These findings have positioned FGL as a potential therapeutic tool for age-related cognitive decline and Alzheimer's disease.

The neuroprotective properties of FGL extend beyond plasticity enhancement. In excitotoxicity models, FGL pretreatment reduces neuronal death by approximately 40-60%, through FGFR-mediated activation of PI3K/Akt pro-survival signalling and upregulation of Bcl-2 family anti-apoptotic proteins. Against amyloid-beta toxicity specifically, FGL reduces both the direct toxicity of oligomeric amyloid and the secondary inflammatory response, making it potentially valuable in Alzheimer's research from multiple mechanistic angles.

FGL is unusual among cognitive-enhancing peptides in demonstrating systemic efficacy after peripheral injection. Most large peptides are either degraded in circulation, unable to cross the blood-brain barrier, or both. FGL's small size (15 amino acids), relative protease resistance, and apparent ability to utilise saturable transport mechanisms across the blood-brain barrier give it practical research advantages over most NCAM-targeting strategies. The peptide has progressed to Phase I clinical trials in Alzheimer's disease, where initial safety data showed acceptable tolerability, though efficacy results at Phase II have not been reported publicly.